Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 107

1.

The Flint Animal Cancer Center (FACC) Canine Tumour Cell Line Panel: a resource for veterinary drug discovery, comparative oncology and translational medicine.

Fowles JS, Dailey DD, Gustafson DL, Thamm DH, Duval DL.

Vet Comp Oncol. 2016 May 19. doi: 10.1111/vco.12192. [Epub ahead of print]

PMID:
27197945
2.

Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology.

LeBlanc AK, Breen M, Choyke P, Dewhirst M, Fan TM, Gustafson DL, Helman LJ, Kastan MB, Knapp DW, Levin WJ, London C, Mason N, Mazcko C, Olson PN, Page R, Teicher BA, Thamm DH, Trent JM, Vail DM, Khanna C.

Sci Transl Med. 2016 Feb 3;8(324):324ps5. doi: 10.1126/scitranslmed.aaf0746. Review.

PMID:
26843188
3.

Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.

Curran K, Thamm DH.

Vet Comp Oncol. 2015 Aug 17. doi: 10.1111/vco.12163. [Epub ahead of print]

PMID:
26279153
4.

What Is Your Diagnosis? Renal adenocarcinoma.

Duffy DJ, Kendall AR, Thamm DH, Marolf AJ.

J Am Vet Med Assoc. 2015 Aug 1;247(3):247-9. doi: 10.2460/javma.247.3.247. No abstract available.

PMID:
26176722
5.

Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.

Burton JH, Venable RO, Vail DM, Williams LE, Clifford CA, Axiak-Bechtel SM, Avery AC, Thamm DH.

J Vet Intern Med. 2015 Jul-Aug;29(4):1098-104. doi: 10.1111/jvim.13573. Epub 2015 Jun 25.

6.

Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.

Gardner HL, London CA, Portela RA, Nguyen S, Rosenberg MP, Klein MK, Clifford C, Thamm DH, Vail DM, Bergman P, Crawford-Jakubiak M, Henry C, Locke J, Garrett LD.

BMC Vet Res. 2015 Jun 11;11:131. doi: 10.1186/s12917-015-0446-1.

7.

Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.

London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, Clifford CA, Rosenberg MP, Vail DM, Williams LE, Cronin KL, Wilson-Robles H, Borgatti A, Henry CJ, Bailey DB, Locke J, Northrup NC, Crawford-Jakubiak M, Gill VL, Klein MK, Ruslander DM, Thamm DH, Phillips B, Post G.

PLoS One. 2015 Apr 29;10(4):e0124889. doi: 10.1371/journal.pone.0124889. eCollection 2015.

9.

Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere.

Pilon JL, Clausen DJ, Hansen RJ, Lunghofer PJ, Charles B, Rose BJ, Thamm DH, Gustafson DL, Bradner JE, Williams RM.

Cancer Chemother Pharmacol. 2015 Apr;75(4):671-82. doi: 10.1007/s00280-015-2675-1. Epub 2015 Jan 24.

10.

Veterinary oncology clinical trials: design and implementation.

Thamm DH, Vail DM.

Vet J. 2015 Aug;205(2):226-32. doi: 10.1016/j.tvjl.2014.12.013. Epub 2014 Dec 19. Review.

PMID:
25582798
11.

Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma.

Morges MA, Burton JH, Saba CF, Vail DM, Burgess KE, Thamm DH.

J Vet Intern Med. 2014 Sep-Oct;28(5):1569-74. doi: 10.1111/jvim.12429.

12.

The immunosignature of canine lymphoma: characterization and diagnostic application.

Johnston SA, Thamm DH, Legutki JB.

BMC Cancer. 2014 Sep 8;14:657. doi: 10.1186/1471-2407-14-657.

13.

Correlation of nodal mast cells with clinical outcome in dogs with mast cell tumour and a proposed classification system for the evaluation of node metastasis.

Weishaar KM, Thamm DH, Worley DR, Kamstock DA.

J Comp Pathol. 2014 Nov;151(4):329-38. doi: 10.1016/j.jcpa.2014.07.004. Epub 2014 Aug 27.

PMID:
25172053
14.

Malignant mesenchymoma with widespread metastasis including bone marrow involvement in a dog.

Weishaar KM, Edmondson EF, Thamm DH, Olver CS.

Vet Clin Pathol. 2014 Sep;43(3):447-52. doi: 10.1111/vcp.12180. Epub 2014 Jul 30.

PMID:
25132008
15.

Serum 25-hydroxyvitamin D concentrations in dogs - correlation with health and cancer risk.

Selting KA, Sharp CR, Ringold R, Thamm DH, Backus R.

Vet Comp Oncol. 2014 Jul 8. doi: 10.1111/vco.12101. [Epub ahead of print]

PMID:
25041357
16.

Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma.

Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH.

Autophagy. 2014 Aug;10(8):1415-25. doi: 10.4161/auto.29165. Epub 2014 May 20.

17.

Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma.

Shoeneman JK, Ehrhart EJ 3rd, Charles JB, Thamm DH.

Vet Comp Oncol. 2016 Jun;14(2):e45-57. doi: 10.1111/vco.12104. Epub 2014 Jun 13.

PMID:
24923332
18.

Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.

Halsey CH, Gustafson DL, Rose BJ, Wolf-Ringwall A, Burnett RC, Duval DL, Avery AC, Thamm DH.

BMC Vet Res. 2014 May 6;10:105. doi: 10.1186/1746-6148-10-105.

19.

Autophagy and cancer therapy.

Thorburn A, Thamm DH, Gustafson DL.

Mol Pharmacol. 2014 Jun;85(6):830-8. doi: 10.1124/mol.114.091850. Epub 2014 Feb 26. Review.

20.

Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma.

Selmic LE, Burton JH, Thamm DH, Withrow SJ, Lana SE.

J Vet Intern Med. 2014 Mar-Apr;28(2):554-63. doi: 10.1111/jvim.12313. Epub 2014 Feb 10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk